Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection

Antimicrob Agents Chemother. 2002 Apr;46(4):1122-4. doi: 10.1128/AAC.46.4.1122-1124.2002.

Abstract

We compared the efficacies of quinupristin-dalfopristin (Q-D; 30 mg/kg of body weight every 8 h) and vancomycin (60 mg/kg twice daily), alone or in combination with rifampin (10 mg/kg twice daily), in a rabbit model of methicillin-resistant Staphylococcus aureus knee prosthesis infection. In contrast to vancomycin, Q-D significantly reduced the mean log(10) CFU per gram of bone versus that for the controls. The combination of rifampin with either Q-D or vancomycin was significantly more effective than monotherapy.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / therapeutic use
  • Antibiotics, Antitubercular / administration & dosage*
  • Drug Synergism
  • Drug Therapy, Combination / pharmacokinetics
  • Drug Therapy, Combination / therapeutic use*
  • Joint Prosthesis*
  • Methicillin Resistance
  • Prosthesis-Related Infections / drug therapy*
  • Prosthesis-Related Infections / microbiology
  • Rabbits
  • Rifampin / administration & dosage*
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / microbiology
  • Tissue Distribution
  • Vancomycin / pharmacokinetics
  • Vancomycin / therapeutic use
  • Virginiamycin / administration & dosage*
  • Virginiamycin / analogs & derivatives

Substances

  • Anti-Bacterial Agents
  • Antibiotics, Antitubercular
  • Virginiamycin
  • quinupristin
  • Vancomycin
  • Rifampin